164 related articles for article (PubMed ID: 36671372)
1. Evaluation of Everolimus Activity against
Bianco DM; De Maio F; Santarelli G; Palucci I; Salustri A; Bianchetti G; Maulucci G; Citterio F; Sanguinetti M; Tamburrini E; Sali M; Delogu G
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671372
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Oral Liposomal Glutathione and In Vitro Everolimus in Altering the Immune Responses against
To K; Cao R; Yegiazaryan A; Owens J; Sasaninia K; Vaughn C; Singh M; Truong E; Sathananthan A; Venketaraman V
Biomol Concepts; 2021 May; 12(1):16-26. PubMed ID: 33966361
[TBL] [Abstract][Full Text] [Related]
3. Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy.
Kilinç G; Boland R; Heemskerk MT; Spaink HP; Haks MC; van der Vaart M; Ottenhoff THM; Meijer AH; Saris A
Microbiol Spectr; 2024 Jun; ():e0016724. PubMed ID: 38916320
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the mTOR Pathway for Tuberculosis Treatment.
Singh P; Subbian S
Front Microbiol; 2018; 9():70. PubMed ID: 29441052
[TBL] [Abstract][Full Text] [Related]
5. Antimycobacterial Effects of Everolimus in a Human Granuloma Model.
Ashley D; Hernandez J; Cao R; To K; Yegiazaryan A; Abrahem R; Nguyen T; Owens J; Lambros M; Subbian S; Venketaraman V
J Clin Med; 2020 Jun; 9(7):. PubMed ID: 32610643
[No Abstract] [Full Text] [Related]
6. Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in
Cerni S; Shafer D; To K; Venketaraman V
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30754665
[TBL] [Abstract][Full Text] [Related]
7. Effects of Everolimus in Modulating the Host Immune Responses against
Raien A; Davis S; Zhang M; Zitser D; Lin M; Pitcher G; Bhalodia K; Subbian S; Venketaraman V
Cells; 2023 Nov; 12(22):. PubMed ID: 37998388
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of HIV-positive patients with non-tuberculous mycobacteria positive culture who received anti-tuberculous treatment in Botswana: Implications of using diagnostic algorithms without non-tuberculous mycobacteria.
Agizew T; Boyd R; Mathebula U; Mathoma A; Basotli J; Serumola C; Pals S; Finlay A; Lekone P; Rankgoane-Pono G; Tlhakanelo T; Chihota V; Auld AF
PLoS One; 2020; 15(6):e0234646. PubMed ID: 32530972
[TBL] [Abstract][Full Text] [Related]
9. Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacterium tuberculosis antigen.
Ghadimi D; de Vrese M; Heller KJ; Schrezenmeir J
Int Immunopharmacol; 2010 Jun; 10(6):694-706. PubMed ID: 20381647
[TBL] [Abstract][Full Text] [Related]
10. Host-directed therapy to combat mycobacterial infections.
Kilinç G; Saris A; Ottenhoff THM; Haks MC
Immunol Rev; 2021 May; 301(1):62-83. PubMed ID: 33565103
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and clinical characteristic of mycobacterial infections in human immunodeficiency virus-infected patients in Siriraj Hospital.
Chayakulkeeree M; Naksanguan T
J Med Assoc Thai; 2015 Mar; 98(3):238-44. PubMed ID: 25920293
[TBL] [Abstract][Full Text] [Related]
12. Host-directed anti-mycobacterial activity of colchicine, an anti-gout drug, via strengthened host innate resistance reinforced by the IL-1β/PGE
Kwon KW; Kim LH; Kang SM; Lee JM; Choi E; Park J; Hong JJ; Shin SJ
Br J Pharmacol; 2022 Aug; 179(15):3951-3969. PubMed ID: 35301712
[TBL] [Abstract][Full Text] [Related]
13. [Evolution of IGRA researches].
Ariga H; Harada N
Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
[TBL] [Abstract][Full Text] [Related]
14. Protein Kinase R Restricts the Intracellular Survival of
Smyth R; Berton S; Rajabalee N; Chan T; Sun J
Front Microbiol; 2020; 11():613963. PubMed ID: 33552025
[TBL] [Abstract][Full Text] [Related]
15. Differential Responses by Human Macrophages to Infection With
Feng Z; Bai X; Wang T; Garcia C; Bai A; Li L; Honda JR; Nie X; Chan ED
Front Microbiol; 2020; 11():116. PubMed ID: 32117140
[No Abstract] [Full Text] [Related]
16. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Wallis RS; Ginindza S; Beattie T; Arjun N; Likoti M; Edward VA; Rassool M; Ahmed K; Fielding K; Ahidjo BA; Vangu MDT; Churchyard G
Lancet Respir Med; 2021 Aug; 9(8):897-908. PubMed ID: 33740465
[TBL] [Abstract][Full Text] [Related]
17. Pasakbumin A controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and production of antibacterial mediators in mouse macrophages.
Lee HJ; Ko HJ; Kim SH; Jung YJ
PLoS One; 2019; 14(3):e0199799. PubMed ID: 30865638
[TBL] [Abstract][Full Text] [Related]
18. Host-Directed Therapeutic Strategies for Tuberculosis.
Kolloli A; Subbian S
Front Med (Lausanne); 2017; 4():171. PubMed ID: 29094039
[TBL] [Abstract][Full Text] [Related]
19. Autophagy: A new strategy for host-directed therapy of tuberculosis.
Paik S; Kim JK; Chung C; Jo EK
Virulence; 2019 Dec; 10(1):448-459. PubMed ID: 30322337
[TBL] [Abstract][Full Text] [Related]
20. Host-Directed Therapies for Tuberculosis.
Jeong EK; Lee HJ; Jung YJ
Pathogens; 2022 Nov; 11(11):. PubMed ID: 36365041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
